/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR
DISSEMINATION IN THE UNITED
STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY
CONSTITUTE A VIOLATION OF UNITED
STATES SECURITIES LAWS/
- RHO Phyto™ Rapid Act Sprays are now available nationwide in
high ratios of CBD to THC and are designed for rapid absorption and
with lemon-mint flavour on the Medical Cannabis by Shoppers™
portal.
- The Rapid Act Sprays are also available for the Medical
Cannabis Real World Evidence Studies (MC-RWE) conducted by the
University Health Network in partnerships with Medical Cannabis by
Shoppers along side RHO Phyto's Micro Drop Oil
formulations.
TORONTO, Sept. 21, 2020 /CNW/ - Avicanna Inc.
("Avicanna" or the "Company") (TSX: AVCN) (OTCQX:
AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the
development, manufacturing and commercialization of plant-derived
cannabinoid-based products, is pleased to announce that its
advanced RHO Phyto Rapid Act Sprays are now officially available
nationwide in Canada on the
Medical Cannabis by Shoppers ("Shoppers") portal, as well as
through the Medical Cannabis Real-World Evidence Study at the
University Health Network.
Avicanna's RHO Phyto product line is now commercially available
after years of research and development through collaborations with
world class academic and clinical organizations. The development of
RHO Phyto products has focused on the key properties in drug
development that health care providers seek when recommending a
medical product to their patients such as formulation stability for
consistent dosing, enhanced absorption and a range of onset
times.
The Rapid Act Spray is a sublingual spray and is among the
second set of Avicanna's RHO Phyto products available for purchase
through Shoppers. The sublingual sprays bypass first-pass
metabolism and are quickly absorbed in the mucosal lining under the
tongue. The RHO Phyto Rapid Act Spray provides an alternative
delivery form to the RHO Phyto Micro Drops (also available for sale
through Shoppers) which are absorbed through the oral route. The
RHO Phyto Rapid Act Sprays have been formulated with specific
ingredients that enhance absorption and the onset time of
cannabinoids across the mucous membrane beneath the tongue. The
lemon-mint flavoured sprays will be available in 10:20 CBD and 2:40
(w/w) THC to CBD ratios.
Dr. Justin Grant, Avicanna's
Executive Vice President of Scientific Affairs, commented, "The RHO
Phyto Rapid Act Sprays are designed for faster onset and can be
used in acute conditions where patients seek faster relief. The
sublingual sprays can also be used to supplement slower and longer
acting products, such as the RHO Phyto Micro Drop, when occasional
higher doses may be required. Sublingual administration provides an
alternative to the potentially harmful effects of consuming
inhalation products."
In August 2020, Avicanna launched
its blood orange flavoured RHO Phyto Micro Drop 2:50 CBD and Micro
Drop 5:20 CBD. In the coming months, Avicanna will be launching its
much-anticipated RHO Phyto Deep Tissue Gel, Daily Cream and Simple
Dose Capsules. To ensure batch-to-batch consistency and
high-quality products, these formulations are manufactured at
MediPharm Labs Inc, a Good Manufacturing Practices ("GMP")
certified facility. In addition to strict GMP manufacturing, all
RHO Phyto products undergo GMP-level analytical testing by Sigma
Analytical Services Inc. and use blockchain technology developed by
TruTrace Technologies Inc. to manage, track and trace each step of
the supply chain.
Detailed guidelines outlining dosing and titration for Health
Care Practitioners ("HCPs") and patients is available on the
RHO Phyto website at www.rhophyto.com. In addition, the Avicanna
Academy includes additional product information for patients,
frequently asked questions, and a recording of Avicanna's 3rd
annual symposium which was hosted virtually in partnership with
Shoppers on July 21, 2020. For more information visit
https://www.avicanna.com/the-avicanna-academy/.
The Company has also re-branded and re-launched its subsidiary,
My Cannabis Clinic (formerly known as My Cannabis), which
specializes in assisting patients to gain access to medical
cannabis and cannabinoid-based products for medical use. My
Cannabis Clinic is devoted to providing HCPs and patients with the
support and education needed for medical cannabis use. My Cannabis
Clinic believes in providing quality care to patients and providing
education on the considerations and potential benefits that
cannabis has to offer for medical use. Information about My
Cannabis Clinic can be found
at https://mycannabisclinic.org/.
About Avicanna
Avicanna is a diversified and vertically integrated Canadian
biopharmaceutical company focused on the research, development, and
commercialization of plant-derived cannabinoid-based products for
the global consumer, medical, and pharmaceutical market
segments.
Avicanna is an established leader in cannabinoid research and
development, which it primarily conducts at its R&D
headquarters in the Johnson & Johnson Innovation Centre, JLABS
@ Toronto, Canada and in collaboration with leading
Canadian academic and medical institutions. In addition to its
developing pharmaceutical pipeline, Avicanna's team of experts have
developed and commercialized several industry leading product
lines, including:
- Pura H&W™: an advanced and clinically tested line of CBD
consumer derma-cosmetic products; and,
- RHO Phyto™: an advanced line of medical cannabis products
containing varying ratios of CBD and THC currently available
nation-wide across Canada in partnership with Medical
Cannabis by Shoppers™, a subsidiary of Shoppers Drug Mart. RHO
Phyto is the first strictly medical formulary of advanced "Cannabis
2.0" products, containing oils, sprays, capsules, creams, and gels,
all developed with scientific rigour, manufactured under GMP
standards and supported by pre-clinical data.
With ongoing clinical trials on its derma-cosmetic (Pura
H&W), medical cannabis (RHO Phyto) and a pipeline of
pharmaceutical products, Avicanna's dedication to researching the
important role that cannabinoids play in an increasingly wider
scope of products has been at the core of the Company's vision
since its inception. Furthermore, Avicanna's commitment to
education is demonstrated through its annual medical symposium, the
Avicanna Academy educational platform, and the My Cannabis Clinic
patient program through its subsidiary company.
Avicanna manages its own supply chain including cultivation and
extraction through its two majority-owned subsidiaries, Sativa
Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., both located
in Santa Marta, Colombia. Through these sustainable,
economical, and industrial scale subsidiaries, Avicanna cultivates,
processes, and commercializes a range of cannabis and hemp
cultivars dominant in CBD, CBG, THC, and other cannabinoids for use
as active pharmaceutical ingredients. Avicanna's Avesta Genetica
program specializes in the development and optimization of rare
cultivars for commercial production along with feminized seeds for
global export. In June 2020, Avicanna made history with a
shipment of hemp seeds to the United
States of America by completing the first ever export
of hemp seeds from Colombia.
SOURCE Avicanna Inc.
Stay Connected
For more information about Avicanna, visit www.avicanna.com,
call 1-647-243-5283, or contact Setu
Purohit, President by email at info@avicanna.com.
Cautionary Note Regarding Forward-Looking Information and
Statements
This news release contains "forward-looking information"
within the meaning of applicable securities laws. Forward-looking
information contained in this press release may be identified by
the use of words such as, "may", "would", "could", "will",
"likely", "expect", "anticipate", "believe, "intend", "plan",
"forecast", "project", "estimate", "outlook" and other similar
expressions, and includes statements with respect to the
ability of the RHO Phyto Rapid Act Sprays to be used in acute
conditions where patients seek faster relief, the ability of
the RHO Phyto Rapid Act Sprays to be used to supplement slower
and longer acting products, the ability of the Company launching
the RHO Phyto Deep Tissue Gel, Daily Cream and Simple Dose
Capsules, the ability of My Cannabis Clinic to provide HCPs
and patients with the support and education needed for medical
cannabis use, and that there is a benefit to using cannabis for
medical purposes. Forward-looking information is not a guarantee of
future performance and is based upon a number of estimates and
assumptions of management in light of management's experience and
perception of trends, current conditions and expected developments,
as well as other factors relevant in the circumstances, including
assumptions in respect of current and future market conditions, the
current and future regulatory environment; and the availability of
licenses, approvals and permits.
Although the Company believes that the expectations and
assumptions on which such forward-looking information is based are
reasonable, undue reliance should not be placed on the
forward-looking information because the Company can give no
assurance that they will prove to be correct. Actual results and
developments may differ materially from those contemplated by these
statements. Forward-looking information is subject to a variety of
risks and uncertainties that could cause actual events or results
to differ materially from those projected in the forward-looking
information. Such risks and uncertainties include, but are not
limited to current and future market conditions, including the
market price of the common shares of the Company, and the risk
factors set out in the Company's annual information form dated
April 15, 2020, filed with the
Canadian securities regulators and available under the Company's
profile on SEDAR at www.sedar.com.
The statements in this press release are made as of the date
of this release. The Company disclaims any intent or obligation to
update any forward-looking information, whether as a result of new
information, future events or results or otherwise, other than as
required by applicable securities laws.
SOURCE Avicanna Inc.
